{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:12:26Z","timestamp":1795093946755,"version":"4.10.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL53392"],"award-info":[{"award-number":["HL53392"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL139968"],"award-info":[{"award-number":["HL139968"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009714","name":"Children's Cardiomyopathy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009714","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyle John Rymiszewski Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Plasma N-terminal prohormone B-type natriuretic peptide (NT-proBNP) concentration is a heart failure (HF) biomarker in adults and children. Its prognostic value for HF-related events has been established only in adults. Therefore, we\u00a0aimed to test the hypothesis that plasma NT-proBNP concentrations predicted the risk of heart transplantation or death in children with HF. We studied the medical records of 109 children with HF enrolled in the IBM Watson Explorys database and from 150 children enrolled in the Pediatric Cardiomyopathy Registry (PCMR). Nonlinear regression was used to assess the relationship between plasma NT-proBNP concentrations and the risk of events in the two cohorts. All children in the PCMR cohort had dilated cardiomyopathy. The Explorys cohort also included children with congenital cardiovascular malformations. Median plasma NT-proBNP concentrations were 1250\u00a0pg\/mL and 184\u00a0pg\/mL in the Explorys and PCMR cohorts, respectively. The percentage of deaths\/heart transplantations was 7%\/22%, over 2\u00a0years in the Explorys cohort and 3%\/16% over 5\u00a0years in the PCMR cohort. Mean estimates of plasma NT-proBNP concentration indicative of half-maximum relative risk for events (EC<jats:sub>50<\/jats:sub> values) at 2 and 5\u00a0years were 3730\u00a0pg\/mL and 4199\u00a0pg\/mL, respectively, values both close to the mean of 3880\u00a0pg\/mL established for adults with HF. The plasma NT-proBNP concentration is suitable for estimating relative risk of mortality and heart transplantation in children with HF, independent of etiology and shows similar relations to clinical outcomes as in adults<jats:bold>,<\/jats:bold> indicating its likely value as a surrogate marker both for adult and pediatric HF.<\/jats:p>\n          <jats:p>ClinicalTrials.gov Identifiers: NCT00005391 (May 26, 2000), NCT01873976 (June 10, 2013).<\/jats:p>","DOI":"10.1007\/s00246-024-03489-7","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T06:41:57Z","timestamp":1715236917000},"page":"694-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["NT-proBNP for Predicting All-Cause Death and Heart Transplant in Children and Adults with Heart Failure"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct00005391","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01873976","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Walter","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Diedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taye H.","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Breitenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Rossano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Lipshultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"3","key":"3489_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","volume":"6","author":"PA Heidenreich","year":"2013","unstructured":"Heidenreich PA, Albert NM, Allen LA et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6(3):606\u2013619. https:\/\/doi.org\/10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"issue":"15","key":"3489_CR2","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jama.2011.1474","volume":"306","author":"J Chen","year":"2011","unstructured":"Chen J, Normand ST, Wang Y, Krumholz HM (2011) National and regional trends in heart failure hospitalization and mortality rates for medicare beneficiaries, 1998\u20132008. JAMA 306(15):1669\u20131678. https:\/\/doi.org\/10.1001\/jama.2011.1474","journal-title":"JAMA"},{"key":"3489_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ahj.2018.11.010","volume":"209","author":"DS Burstein","year":"2019","unstructured":"Burstein DS, Shamszad P, Dai D et al (2019) Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults. Am Heart J 209:9\u201319. https:\/\/doi.org\/10.1016\/j.ahj.2018.11.010","journal-title":"Am Heart J"},{"issue":"6","key":"3489_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.106.621185","volume":"115","author":"SD Colan","year":"2007","unstructured":"Colan SD, Lipshultz SE, Lowe AM et al (2007) Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the pediatric cardiomyopathy registry. Circulation 115(6):773\u2013781. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.621185","journal-title":"Circulation"},{"issue":"21","key":"3489_CR5","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1016\/j.jacc.2017.09.1089","volume":"70","author":"RK Singh","year":"2017","unstructured":"Singh RK, Canter CE, Shi L et al (2017) Survival without cardiac transplantation among children with dilated cardiomyopathy. J Am Coll Cardiol 70(21):2663\u20132673. https:\/\/doi.org\/10.1016\/j.jacc.2017.09.1089","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3489_CR6","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1116\/CIRCULATIONAHA.112.104638","volume":"126","author":"SA Webber","year":"2012","unstructured":"Webber SA, Lipshultz SE, Sleeper LA et al (2012) Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the pediatric cardiomyopathy registry. Circulation 126(10):1237\u20131244. https:\/\/doi.org\/10.1116\/CIRCULATIONAHA.112.104638","journal-title":"Circulation"},{"issue":"3","key":"3489_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ahj.2012.04.018","volume":"164","author":"JD Wilkinson","year":"2012","unstructured":"Wilkinson JD, Lowe AM, Salbert BA et al (2012) Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the pediatric cardiomyopathy registry. Am Heart J 164(3):442\u2013448. https:\/\/doi.org\/10.1016\/j.ahj.2012.04.018","journal-title":"Am Heart J"},{"issue":"12","key":"3489_CR8","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.cjca.2013.08.008","volume":"29","author":"PF Kantor","year":"2013","unstructured":"Kantor PF, Lougheed J, Dancea A et al (2013) Presentation, diagnosis, and medical management of heart failure in children: Canadian cardiovascular society guidelines. Can J Cardiol 29(12):1535\u20131552. https:\/\/doi.org\/10.1016\/j.cjca.2013.08.008","journal-title":"Can J Cardiol"},{"issue":"9","key":"3489_CR9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.healun.2014.06.002","volume":"33","author":"R Kirk","year":"2014","unstructured":"Kirk R, Dipchand AI, Rosenthal DN et al (2014) The international society for heart and lung transplantation guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant 33(9):888\u2013909. https:\/\/doi.org\/10.1016\/j.healun.2014.06.002","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"3489_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","volume":"70","author":"D Bonnet","year":"2017","unstructured":"Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF (2017) Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol 70(10):1262\u20131272. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.725","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3489_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1116\/CIRCULATIONAHA.113.003615","volume":"129","author":"JW Rossano","year":"2014","unstructured":"Rossano JW, Shaddy RE (2014) Update on pharmacological heart failure therapies in children: do adult medications work in children and if not, why not? Circulation 129(5):607\u201312. https:\/\/doi.org\/10.1116\/CIRCULATIONAHA.113.003615","journal-title":"Circulation"},{"issue":"10","key":"3489_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jama.298.10.1171","volume":"298","author":"RE Shaddy","year":"2007","unstructured":"Shaddy RE, Boucek MM, Hsu DT et al (2007) Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298(10):1171\u20131179. https:\/\/doi.org\/10.1001\/jama.298.10.1171","journal-title":"JAMA"},{"issue":"36","key":"3489_CR13","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"10","key":"3489_CR14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1161\/CIRCULATIONAHA.105.608869","volume":"114","author":"JF Price","year":"2006","unstructured":"Price JF, Thomas AK, Grenier M et al (2006) B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 114(10):1063\u20131069. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.608869","journal-title":"Circulation"},{"issue":"5","key":"3489_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCHEARTFAILURE.109.906875","volume":"3","author":"SR Auerbach","year":"2010","unstructured":"Auerbach SR, Richmond ME, Lamour JM et al (2010) BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the pediatric carvedilol trial. Circ Heart Fail 3(5):606\u2013611. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.906875","journal-title":"Circ Heart Fail"},{"issue":"11","key":"3489_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.amjcard.2016.08.053","volume":"118","author":"SL den Boer","year":"2016","unstructured":"den Boer SL, Rizopoulos D, du Marchie Sarvaas GJ et al (2016) Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements to predict cardiac death in acute and chronic dilated cardiomyopathy in children. Am J Cardiol 118(11):1723\u20131729. https:\/\/doi.org\/10.1016\/j.amjcard.2016.08.053","journal-title":"Am J Cardiol"},{"issue":"2","key":"3489_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10741-021-10136-3","volume":"27","author":"TA Buchan","year":"2022","unstructured":"Buchan TA, Ching C, Foroutan F et al (2022) Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis. Heart Fail Rev 27(2):645\u2013654. https:\/\/doi.org\/10.1007\/s10741-021-10136-3","journal-title":"Heart Fail Rev"},{"issue":"2","key":"3489_CR18","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ehf2.13233","volume":"8","author":"M van der Meulen","year":"2021","unstructured":"van der Meulen M, den Boer S, du Marchie Sarvaas GJ et al (2021) Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome. ESC Heart Fail 8(2):1472\u20131481. https:\/\/doi.org\/10.1002\/ehf2.13233","journal-title":"ESC Heart Fail"},{"issue":"2","key":"3489_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/cpt.2222","volume":"110","author":"W Schmitt","year":"2021","unstructured":"Schmitt W, Ruhs H, Burghaus R et al (2021) NT-proBNP qualifies as a surrogate for clinical endpoints in heart failure. Clin Pharmacol Ther 110(2):498\u2013507. https:\/\/doi.org\/10.1002\/cpt.2222","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"3489_CR20","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.jacc.2021.08.056","volume":"78","author":"J Palm","year":"2021","unstructured":"Palm J, Holdenrieder S, Hoffmann G et al (2021) Predicting major adverse cardiovascular events in children with age-adjusted NT-proBNP. J Am Coll Cardiol 78(19):1890\u20131900. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.056","journal-title":"J Am Coll Cardiol"},{"issue":"2 Pt 3","key":"3489_CR21","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1067\/mhj.2000.103933","volume":"139","author":"MA Grenier","year":"2000","unstructured":"Grenier MA, Osganian SK, Cox GF et al (2000) Design and implementation of the North American pediatric cardiomyopathy registry. Am Heart J 139(2 Pt 3):S86-95. https:\/\/doi.org\/10.1067\/mhj.2000.103933","journal-title":"Am Heart J"},{"key":"3489_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ppedcard.2019.02.004","volume":"53","author":"MD Everitt","year":"2019","unstructured":"Everitt MD, Wilkinson JD, Shi L et al (2019) Cardiac biomarkers in pediatric cardiomyopathy: study design and recruitment results from the pediatric cardiomyopathy registry. Prog Pediatr Cardiol 53:1\u201310. https:\/\/doi.org\/10.1016\/j.ppedcard.2019.02.004","journal-title":"Prog Pediatr Cardiol"},{"issue":"3","key":"3489_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/ehf2.12665","volume":"7","author":"J Huusko","year":"2020","unstructured":"Huusko J, Purmonen T, Toppila I, Lassenius M, Ukkonen H (2020) Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction. ESC Heart Fail 7(3):1039\u20131048. https:\/\/doi.org\/10.1002\/ehf2.12665","journal-title":"ESC Heart Fail"},{"issue":"10","key":"3489_CR24","doi-asserted-by":"publisher","first-page":"e002423","DOI":"10.1161\/JAHA.115.002423","volume":"4","author":"R Kerkela","year":"2015","unstructured":"Kerkela R, Ulvila J, Magga J (2015) Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc 4(10):e002423. https:\/\/doi.org\/10.1161\/JAHA.115.002423","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"3489_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.amjcard.20210.10.015","volume":"107","author":"DTH Wong","year":"2011","unstructured":"Wong DTH, George K, Wilson J et al (2011) Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure. Am J Cardiol 107(4):573\u2013578. https:\/\/doi.org\/10.1016\/j.amjcard.20210.10.015","journal-title":"Am J Cardiol"},{"issue":"15","key":"3489_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.jacc.2009.06.020","volume":"54","author":"YM Law","year":"2009","unstructured":"Law YM, Hoyer AW, Reller MD, Silberbach M (2009) Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the better not pout children. J Am Coll Cardiol 54(15):1467\u20131475. https:\/\/doi.org\/10.1016\/j.jacc.2009.06.020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3489_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.amjcard.2004.10.014","volume":"95","author":"YM Law","year":"2005","unstructured":"Law YM, Keller BB, Feingold BM, Boyle GJ (2005) Usefulness of plasma B-type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Am J Cardiol 95(4):474\u2013478. https:\/\/doi.org\/10.1016\/j.amjcard.2004.10.014","journal-title":"Am J Cardiol"},{"issue":"6","key":"3489_CR28","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00246-021-02611-3","volume":"42","author":"R Morales-Demori","year":"2021","unstructured":"Morales-Demori R, Montanes E, Erkonen G, Chance M, Anders M, Denfield S (2021) Epidemiology of pediatric heart failure in the USA-a 15-year multi-institutional study. Pediatr Cardiol 42(6):1297\u20131307. https:\/\/doi.org\/10.1007\/s00246-021-02611-3","journal-title":"Pediatr Cardiol"},{"issue":"9","key":"3489_CR29","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.amjcard.2013.07.007","volume":"112","author":"G Kim","year":"2013","unstructured":"Kim G, Lee OJ, Kang IS, Song J, Huh J (2013) Clinical implications of serial serum N-terminal prohormone brain natriuretic peptide levels in the prediction of outcome in children with dilated cardiomyopathy. Am J Cardiol 112(9):1455\u20131460. https:\/\/doi.org\/10.1016\/j.amjcard.2013.07.007","journal-title":"Am J Cardiol"},{"issue":"1","key":"3489_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/eurjhf\/hfn001","volume":"11","author":"J Mangat","year":"2009","unstructured":"Mangat J, Carter C, Riley G, Foo Y, Burch M (2009) The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail 11(1):48\u201352. https:\/\/doi.org\/10.1093\/eurjhf\/hfn001","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"3489_CR31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ahj.2010.07.012","volume":"160","author":"PG Rusconi","year":"2010","unstructured":"Rusconi PG, Ludwig DA, Ratnasamy C et al (2010) Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure. Am Heart J 160(4):776\u2013783. https:\/\/doi.org\/10.1016\/j.ahj.2010.07.012","journal-title":"Am Heart J"},{"issue":"8","key":"3489_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","volume":"318","author":"GM Felker","year":"2017","unstructured":"Felker GM, Anstrom KJ, Adams KF et al (2017) Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318(8):713\u2013720. https:\/\/doi.org\/10.1001\/jama.2017.10565","journal-title":"JAMA"},{"issue":"3","key":"3489_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ahj.2007.11.001","volume":"155","author":"C Ratnasamy","year":"2008","unstructured":"Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P (2008) Associations between neurohormal and inflammatory activation and heart failure in children. Am Heart J 155(3):527\u2013533. https:\/\/doi.org\/10.1016\/j.ahj.2007.11.001","journal-title":"Am Heart J"},{"issue":"3","key":"3489_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00246-022-02960-7","volume":"44","author":"B Das","year":"2023","unstructured":"Das B, Despande S, Akam-Venkata J, Shakti D, Moskowitz W, Lipshultz SE (2023) Heart failure with preserved ejection fraction in children. Pediatr Cardiol 44(3):513\u2013529. https:\/\/doi.org\/10.1007\/s00246-022-02960-7","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"3489_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41390-021-01698-x","volume":"92","author":"MRF Gropler","year":"2022","unstructured":"Gropler MRF, Lipshultz SE, Wilkinson JD, Towbin JA, Colan SD, Canter CE, Lavine KJ, Simpson KE (2022) Pediatric and adult dilated cardiomyopathy are distinguished by distinct biomarker profiles. Pediatr Res 92(1):206\u2013215. https:\/\/doi.org\/10.1038\/s41390-021-01698-x","journal-title":"Pediatr Res"},{"issue":"2","key":"3489_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIR.0000000000001151","volume":"148","author":"C Bogle","year":"2023","unstructured":"Bogle C, Colan SD, Miyamoto SD, Choudhry S, Baez-Hernandez N, Brickler MM, Feingold B, Lal AK, Lee TM, Canter CE, Lipshultz SE (2023) Treatment strategies for cardiomyopathy in children. A scientific statement from the American Heart Association. Circulation 148(2):174\u2013195. https:\/\/doi.org\/10.1161\/CIR.0000000000001151","journal-title":"Circulation"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-024-03489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-024-03489-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-024-03489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:09:21Z","timestamp":1740056961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-024-03489-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3489"],"URL":"https:\/\/doi.org\/10.1007\/s00246-024-03489-7","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JR is a consultant for Abiomed, Bayer, Cytokinetics, and Myokardia. WS, CD, MM, TE, and SB are employees of Bayer AG and may own stock in the company; TH and SL report no competing interests but SL reports being the chair of the Children\u2019s Cardiomyopathy Foundation (CCF) medical advisory board and their Chief Medical Officer. SL is also on the medical advisory board of Secretome Therapeutics, was also a Bayer consultant,  and a member of the Roche DSMB. SL has also served in the following editorial roles: American College of Cardiology (Editor), Elsevier (Editor), Biomed Central (Editor), American Heart Association (Scientific Statement Chair).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}